This Year's Highlights

• In 2005, Kereos completed a very successful Series B venture financing. Details to be announced around the time of this Forum
• In 2004, Kereos announced a significant collaboration with Bristol-Myers Squibb Medical Imaging, Inc. for the development of MRI agents for cardiovascular disease.
• In 2001, Kereos initiated a collaboration with Philips Medical Systems on the development of molecular imaging agents.

Anticipated Highlights

• Two lead candidates -- KI-0001 and KI-1001 -- are anticipated to enter the clinic in 2006.
• Lead candidate nomination for targeted unstable plaque therapeutic.
• Additional significant partnerships in both cancer and cardiovascular disease are expected in the next 12-24 months.

Corporate Mission

Kereos, Inc. develops products designed to provide more effective treatment and detection of cancer, the first two of which are expected to enter clincial trials in 2006. With partners it is also developing candidates for cardiovascular disease imaging and therapy.

Because Kereos' targeted therapeutics seek out definitive biomarkers and carry powerful payloads of proven chemotherapeutics, their specificity and potency make them potentially more effective and less toxic in treating disease. Similarly, the specificity and unique capabilities of Kereos targeted imaging agents enable earlier and more precise diagnosis of disease.